Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia

Lucy Swift, PhD, Chunfen Zhang, MD, Ravi Shah, MD, Tanya Trippett, MD, Aru Narendran, MD PhD

Blood (2018) 132 (Supplement 1): 5207.

https://doi.org/10.1182/blood-2018-99-119438

Published: 2018

Journal Articles

Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation

Lisa Giulino Roth, MD, Tara O'Donohue MD, Tanya Trippett, MD, Elizabeth Klein, MPH, Nancy A. Kernan, MD, Rachel Kobos, MD, Susan Prockop, MD, Andromachi Scaradavou, MD, Neerav Shukla, MD, Peter G Steinherz, MD, Alison J Moskowitz, MD, Craig H. Moskowitz, MD, Farid Boulad, MD

Blood (2015) 126 (23): 2000.

https://doi.org/10.1182/blood.V126.23.2000.2000

Published: 2015

Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Amir T Fathi, MD, Uma Borate, MD, Daniel J. DeAngelo, MD PhD, Maureen M. O'Brien, MD, Tanya Trippett, MD, Bijal D Shah, Gregory A. Hale, MD, James M. Foran, MD, Lewis B. Silverman, MD, Raoul Tibes, MD PhD, Stuart Cramer, D.O., Melinda Pauly, MD, Stella Kim, Ana Kostic, MD, Xiaohui Huang, Yang Pan, PhD, Robert Chen

Blood (2015) 126 (23): 1328.

https://doi.org/10.1182/blood.V126.23.1328.1328

Published: 2015

Journal Articles

I n Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib

Aarthi Jayanthan, Yibing Ruan, PhD, Meaghan Hagerty, Ravi Shah, Tony Truong, MD, Victor A. Lewis, MD, Jessica Boklan, MD, Tanya Trippett, MD, Lia Gore, MD, Aru Narendran, MD, PhD

Blood (2013) 122 (21): 2673.

https://doi.org/10.1182/blood.V122.21.2673.2673

Published: 2013

Journal Articles

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Tim Illidge, Reda Bouabdallah, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Craig H. Moskowitz, MD, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, MD, Andrei R. Shustov, MD, Herve Tilly, MD, Tanya Trippett, MD, Laurie E. Grove, PA-C, Ranjana H. Advani, MD

Blood (2011) 118 (21): 3091.

https://doi.org/10.1182/blood.V118.21.3091.3091

Published: 2011

Journal Articles

Targeting the Bcl-2 Family of Proteins in Hodgkin Lymphoma: In Vitro Cytotoxicity, Target Modulation and Drug Combination Studies of the BH3 Mimetic ABT-737

Aarthi Jayanthan, BS, Scott C Howard, MD, Tanya Trippett, MD, Terzah M. Horton, MD, PhD, Lara Daisley, Victor A. Lewis, MD, Aru Narendran, MD., Ph.D

Blood (2008) 112 (11): 3626.

https://doi.org/10.1182/blood.V112.11.3626.3626

Published: 2008

Journal Articles

Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

Allen R. Chen, MD, PhD, MHS, Robert Hutchison, MD, Allan Hess, PhD, Sharon Gardner, MD, Tanya Trippett, MD, Pedro de Alarcon, MD, Shirley Hogan, PharmD, Joy Mitchell, CRA, Vickie Massey, MD, Louis S. Constine, MD, Lu Chen, PhD, Cindy L. Schwartz, MD

Blood (2007) 110 (11): 1896.

https://doi.org/10.1182/blood.V110.11.1896.1896

Published: 2007

Journal Articles

Allogeneic or Autologous Stem Cell Transplantation (SCT) for the Treatment of Pediatric Patients with Non-Hodgkins Lymphoma (NHL).

Rosanna Ricafort, MD, Tanya Trippett, MD, Nancy A. Kernan, MD, Trudy N. Small, MD, Susan Prockop, MD, Andromachi Scaradavou, MD, Anna Keating, MD, Richard J. O’Reilly, MD, Farid Boulad, MD

Blood (2005) 106 (11): 2093.

https://doi.org/10.1182/blood.V106.11.2093.2093

Published: 2005

Journal Articles

Cyclosporine, Interferon-γ , and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study.

Allen Chen, MD, PhD, Allan Hess, PhD, Sharon Gardner, MD, Tanya Trippett, MD, Pedro de Alarcon, MD, Robert Guillerman, MD, Shirley Hogan, PharmD, Joy Mitchell, Alan Gamis, MD, Vicki Massey, MD, Louis S. Constine, MD, Doojduen Villaluna, MS, Richard Sposto, MD, Cindy Schwartz, MD

Blood (2005) 106 (11): 2087.

https://doi.org/10.1182/blood.V106.11.2087.2087

Published: 2005

NARROW

In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia

Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

I n Vitro Growth Inhibition, Target Modulation and Drug Synergy In Pediatric Leukemia By The Novel Proteasome Inhibitor Carfilzomib

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Targeting the Bcl-2 Family of Proteins in Hodgkin Lymphoma: In Vitro Cytotoxicity, Target Modulation and Drug Combination Studies of the BH3 Mimetic ABT-737

Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

Allogeneic or Autologous Stem Cell Transplantation (SCT) for the Treatment of Pediatric Patients with Non-Hodgkins Lymphoma (NHL).

Cyclosporine, Interferon-γ , and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only